{
    "assertions": [
        {
            "id": 53,
            "context": "Metastatic",
            "deprecated": false,
            "description": "The U.S. Food and Drug Administration (FDA) granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, as detected by an FDA-approved test.",
            "disease": {
                "name": "Myelodysplastic Syndromes",
                "oncotree_code": "MDS",
                "oncotree_term": "Myelodysplastic Syndromes"
            },
            "therapy": {
                "name": "Selpercatinib",
                "type": "Targeted therapy",
                "strategy": "RET inhibition",
                "resistance": "",
                "sensitivity": 1
            },
            "predictive_implication": "FDA-Approved",
            "favorable_prognosis": "",
            "created_on": "01/27/25",
            "last_updated": "2024-06-03",
            "submitted_by": "breardon@broadinstitute.org",
            "validated": true,
            "source_id": 35,
            "variant": {
                "id": 52,
                "feature_type": "rearrangement",
                "gene1": "RET",
                "gene2": null,
                "locus": null,
                "rearrangement_type": "Fusion",
                "feature": "RET Fusion"
            }
        },
        {
            "id": 519,
            "context": "",
            "deprecated": false,
            "description": "Certain missesnse mutations may predict resistance to RET inhibitors",
            "disease": {
                "name": "Myelodysplasia",
                "oncotree_code": "MDS",
                "oncotree_term": "Myelodysplasia"
            },
            "therapy": {
                "name": "LOXO-292",
                "type": "Targeted therapy",
                "strategy": "RET inhibition",
                "resistance": 1,
                "sensitivity": ""
            },
            "predictive_implication": "Clinical evidence",
            "favorable_prognosis": "",
            "created_on": "01/27/25",
            "last_updated": "2019-06-13",
            "submitted_by": "breardon@broadinstitute.org",
            "validated": true,
            "source_id": 161,
            "variant": {
                "id": 519,
                "alternate_allele": "A",
                "cdna_change": "c.2410G>A",
                "chromosome": "10",
                "end_position": "43614996",
                "exon": "14",
                "feature_type": "somatic_variant",
                "gene": "RET",
                "protein_change": "p.V804M",
                "reference_allele": "G",
                "rsid": "rs79658334",
                "start_position": "43614996",
                "variant_annotation": "Missense",
                "feature": "RET p.V804M (Missense)"
            }
        }
    ],
    "sources": [
        {
            "id": 35,
            "type": "FDA",
            "doi": "",
            "nct": "",
            "pmid": "",
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf",
            "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020."
        },
        {
            "id": 161,
            "type": "Journal",
            "doi": "10.1093/annonc/mdy137",
            "nct": "",
            "pmid": 29912274,
            "url": "https://doi.org/10.1093/annonc/mdy137",
            "citation": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876."
        }
    ],
    "variants": [
        {
            "id": 52,
            "feature_type": "rearrangement",
            "gene1": "RET",
            "gene2": null,
            "locus": null,
            "rearrangement_type": "Fusion",
            "feature": "RET Fusion"
        },
        {
            "id": 519,
            "alternate_allele": "A",
            "cdna_change": "c.2410G>A",
            "chromosome": "10",
            "end_position": "43614996",
            "exon": "14",
            "feature_type": "somatic_variant",
            "gene": "RET",
            "protein_change": "p.V804M",
            "reference_allele": "G",
            "rsid": "rs79658334",
            "start_position": "43614996",
            "variant_annotation": "Missense",
            "feature": "RET p.V804M (Missense)"
        }
    ],
    "genes": ["RET"]
}
